Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


NZ company finds major error with cold and flu products

New Zealand company finds major formulation error with cold and flu products worth NZ$1.4 billion worldwide

AFT Pharmaceuticals has identified a major error with the formulation of over 1300 cold and flu products used around the world.

Many over the counter cold and flu products combine phenylephrine and paracetamol. The company’s groundbreaking research has revealed that when combined with paracetamol the level of phenylephrine is effectively twice what it should be.

AFT Pharmaceutical’s findings have been published today in the New England Journal of Medicine. The Journal is considered to be the most prestigious medical journal in the world. “Frankly this is a pretty big finding, with huge implications for this category of product, and it’s reflected in the fact that the New England Journal of Medicine has published what we have found,” said Dr Hartley Atkinson, Managing Director of AFT Pharmaceuticals.

“This is a very significant finding given the volume of over the counter cold and flu products that are consumed each year,” said Dr Atkinson. “The standard dose of phenylephrine in these products is 10mg. That’s all the drug regulatory authorities have allowed. But unbeknown to everyone including the regulators, when you add phenylephrine to paracetamol, the concentration of phenylephrine spikes to roughly 20mg because of the way the human body processes both drugs together. Basically this research tells us that people have inadvertently been taking the equivalent of double the recommended levels of phenylephrine.”

The use of phenylephrine together with paracetamol has increased significantly in recent years. Previously paracetamol was typically combined with pseudoephedrine. But in many countries pseudoephedrine-based products are now only available on prescription because of pseudoephedrine’s use in making the illegal drug methamphetamine.

“This is what makes these findings so important,” says Dr Atkinson. “Phenylephrine has been the ready replacement for pseudoephedrine in cold and flu remedies globally. But the international pharmaceutical companies and drug regulators haven’t known about the interaction between these two drugs. Until now.”

The side effects of an increased amount of phenylephrine may include nervousness, feelings of being unwell, and possibly increased blood pressure. People susceptible to cardiovascular effects may require extra care. But Dr Atkinson said that addressing the consequences of AFT Pharmaceutical’s findings are now in the hands of others. “We immediately informed Medsafe (NZ) and the Therapeutic Goods Administration (Australia) of our findings. It is now up to the regulators to use the information as they see fit. We have also met with the United States Food and Drug Administration in January this year to fully inform them of our findings.”

AFT Pharmaceutical’s discovery was the result of its standard analgesics research programme. The company has now reformulated its cold and flu medication and invented a new formulation that delivers the intended 10mg of phenylephrine to consumers when given in combination with paracetamol. This new product is ready to be filed within the next month for regulatory evaluation in New Zealand and Australia.

These unexpected findings have thrown the international spotlight on AFT Pharmaceuticals. Dr Atkinson says the business has come a long way since it started in a room off his home garage in the late 1990s. “We’ve put a lot of time and effort into researching new products. It’s what drives us as a company and it’s paying off.” He says that this discovery, together with several other innovative new products in the pipeline, means that the future of AFT Pharmaceuticals is extremely bright.

Background to AFT

AFT Pharmaceuticals is a privately-owned New Zealand pharmaceutical company based in Auckland and Sydney. Beginning with a humble $50,000 start-up in Dr Hartley Atkinson’s home garage in 1997, AFT is now an originator of ground-breaking medicine with turnover over NZ$66 million. AFT Pharmaceuticals has over 60 products listed on New Zealand’s Pharmaceutical Schedule and sells medicines in most public and private hospitals across New Zealand. The company has recently opened offices in Kuala Lumpur and Singapore.

END

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Must Sell 20 Petrol Stations: Z Cleared To Buy Caltex Assets

Z Energy is allowed to buy the Caltex and Challenge! petrol station chains but must sell 19 of its retail sites and one truck-stop, the Commerce Commission has ruled in a split decision that acknowledges possible retail price coordination between fuel retailers occurs in some regions. More>>

ALSO:

Huntly: Genesis Extends Life Of Coal-Fuelled Power Station To 2022

Genesis Energy will keep its two coal and gas-fired units at Huntly Power Station operating until 2022, having previously said they'd be closed by 2018, after wringing a high price from other electricity generators who wanted to keep them as back-up. More>>

ALSO:

Dammed If You Do: Ruataniwha Irrigation Scheme Hits Farmer Uptake Targets

Enough Hawke's Bay farmers have signed up for water from the proposed Ruataniwha Water Storage Scheme for it to go ahead as long as a cornerstone institutional capital investor can be found to back it, its regional council promoter announced. More>>

ALSO:

Reserve Bank: OCR Stays At 2.25%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2.25 percent, in a decision traders had said could go either way, while predicting inflation will pick up as the slump in oil prices washes out of the data and capacity pressures start to build in the economy. More>>

ALSO:

Export Values Down: NZ Posts Biggest Annual Trade Deficit In 7 Years

New Zealand has recorded its biggest annual trade deficit since April 2009, reflecting weaker prices of agricultural commodities such as dairy products, beef and lamb, and increased imports of vehicles and machinery. More>>

ALSO:

Currency Events: NZ's New $5 Note Wins International Banknote Award

New Zealand’s new Brighter Money $5 note has been named Banknote of the Year in a prestigious international competition. The $5 note was awarded the IBNS Banknote of the Year title at the International Bank Note Society’s annual meeting. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news